Hereditary Cancer Syndromes
Most cancer is caused by mutations acquired over a person's lifetime (somatic mutations) due to aging, environment, or random chance. However, about 5-10% of all cancers are strongly linked to an inherited gene mutation that is passed down in families (germline mutations).
1. Somatic vs. Germline Mutations
Understanding the difference is critical for both biology and bioinformatics:
- Somatic mutations: Occur only in certain cells (the tumor cells) over the course of life. They are not passed to children. If you sequence the tumor, you will find the mutation; if you sequence the patient's normal blood, you won't.
- Germline mutations: Inherited from a parent and present in every cell of the patient's body from birth. These can be passed to children. If you sequence the tumor, you will find the mutation; if you sequence the patient's blood, you will also find it.
Patients with a germline mutation in a cancer susceptibility gene are born with one "hit" already present in every cell. According to the Two-Hit Hypothesis, they only need one somatic mutation (the second hit) in the remaining healthy allele for cancer to develop, explaining why hereditary cancers often occur at a much younger age than sporadic cancers.
2. Key Hereditary Cancer Syndromes
Hereditary Breast and Ovarian Cancer (HBOC) Syndrome
- Genes: BRCA1, BRCA2 (and others like PALB2).
- Associated Cancers: Breast (often at a young age), ovarian, prostate, and pancreatic cancers.
- Mechanism: These genes are critical for repairing double-strand DNA breaks via Homologous Recombination (HR). When they are defective, cells accumulate genetic errors rapidly.
- Clinical Action: High-risk screening (e.g., breast MRIs at young ages), prophylactic surgeries (mastectomy, oophorectomy), and specific targeted therapies like PARP inhibitors (which exploit the broken DNA repair mechanism via synthetic lethality).
Lynch Syndrome (Hereditary Non-Polyposis Colorectal Cancer)
- Genes: MLH1, MSH2, MSH6, PMS2, EPCAM.
- Associated Cancers: Colorectal, endometrial, ovarian, stomach, and others.
- Mechanism: Defective Mismatch Repair (MMR) system. These proteins normally fix "typos" made when DNA is copied. Tumors with this defect accumulate thousands of mutations (high Tumor Mutational Burden, or TMB), leading to a state called Microsatellite Instability (MSI-High).
- Clinical Action: Frequent colonoscopies starting at young ages. Interestingly, because these tumors have so many mutations, they generate many abnormal proteins (neoantigens), making them highly susceptible to immunotherapy (checkpoint inhibitors).
Li-Fraumeni Syndrome
- Gene: TP53 (the "guardian of the genome").
- Associated Cancers: Sarcomas, breast cancer, brain tumors, adrenocortical carcinoma, and leukemias.
- Mechanism: TP53 normally stops cell division if DNA is damaged or triggers apoptosis if the damage is unrepairable. Without it, cells with severe damage continue to divide.
- Clinical Action: Intensive whole-body MRI screening regimens, as patients have a nearly 100% lifetime risk of developing cancer, often in childhood or early adulthood. Avoidance of radiation therapy when possible, as radiation can cause secondary cancers in these patients.
Familial Adenomatous Polyposis (FAP)
- Gene: APC.
- Associated Cancers: Colorectal cancer.
- Mechanism: Defect in the Wnt signaling pathway. Patients develop hundreds to thousands of polyps in their colon starting in their teenage years. Without intervention, the risk of colorectal cancer is virtually 100%.
- Clinical Action: Prophylactic colectomy (removal of the colon) is usually required in young adulthood.
3. Genetic Counseling and Cascade Testing
When a patient is diagnosed with a hereditary cancer syndrome, it doesn't just affect their own treatment plan—it affects their entire family.
- Genetic Counseling: A specialized process where patients learn about their genetic risks, the implications of testing, and medical management options.
- Cascade Testing: Once a specific pathogenic mutation (e.g., a BRCA1 variant) is identified in a patient, their close relatives (parents, siblings, children) are systematically tested for that exact mutation. This allows relatives who carry the gene to start aggressive screening or prophylactic measures before cancer develops, and spares those who didn't inherit the gene from unnecessary anxiety and procedures.
4. Implications for Data and Tech
For technologists building oncology systems:
- Consent and Privacy: Germline data requires extremely strict data governance. Unlike somatic data, revealing a patient's germline mutation inherently reveals health risks for their siblings and children.
- Variant Classification: A mutation found in sequencing must be classified. The ClinVar database is the standard for interpreting germline variants (e.g., Pathogenic, Benign, Variant of Uncertain Significance - VUS).
- Paired Sequencing: Modern tumor profiling often sequences the tumor and a normal tissue sample (like blood) simultaneously. This is called "Tumor-Normal Paired Sequencing", and it is essential to mathematically subtract the patient's germline background to accurately identify the somatic mutations actually driving the tumor.